Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma

Haematologica

Volumn 87, Issue 7, 2002, Pages 779-781

  Patriarca, Francesca ^a   Sperotto, Alessandra ^a   Fili, Carla ^a   Zaja, Francesco ^a   Prosdocimo, Simonetta ^a   Fanin, Renato ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Autologous stem cell transplantation; Induction therapy; Multiple myeloma; VAD

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; CYTARABINE; VAD REGIMEN;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; HUMAN; MULTIPLE MYELOMA; PLASMACYTOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; LETTER; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036073206     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
2. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
3. Prognostic factors in autologous stem cell transplantation in multiple myeloma: An EBMT Registry Study
4. Autotransplants in multiple myeloma: What have we learned?
5. Autologous transplantation in multiple myeloma: A GITMO retrospective analysis on 290 patients
6. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haemopoietic stem cell transplantation
7. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: Biological and clinical implications
8. VAD-based regimens as primary treatment for multiple myeloma
9. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Result of a multicenter sequential randomized clinical trial
10. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma